Frank Rimerman Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$272K Buy
+3,880
New +$201K 0.02% 536
2024
Q3
Sell
-3,152
Closed -$374K 555
2024
Q2
$374K Buy
3,152
+2,451
+350% +$310K 0.03% 405
2024
Q1
$74.7K Buy
+701
New +$70.7K 0.01% 115
2021
Q4
Sell
-556
Closed -$214K 120
2021
Q3
$214K Buy
+556
New +$205K 0.08% 103

Other funds holding MRNA

Frank Rimerman Advisors's MRNA Position: Q2 2026 in Review

Frank Rimerman Advisors opened a new position in Moderna (MRNA) in Q2 2026: 3,880 shares worth $272K. The stake represents 0.02% of the portfolio and ranks #536 among its holdings. This is a return to the name: Frank Rimerman Advisors previously reported a position in MRNA as recently as Q2 2024.

Frank Rimerman Advisors first reported a position in MRNA in Q3 2021 and has held it in 4 quarters since. The position peaked at $374K in Q2 2024. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Frank Rimerman Advisors held 3,880 shares of Moderna worth $272K as of Q2 2026.
  • Moderna was a new Frank Rimerman Advisors position in Q2 2026.
  • Moderna made up 0.02% of Frank Rimerman Advisors's portfolio in Q2 2026, its #536 holding.
  • Frank Rimerman Advisors first reported a position in Moderna in Q3 2021 and has held it in 4 quarters since.
  • Frank Rimerman Advisors's Moderna position peaked at $374K in Q2 2024.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.